Search Results

Saved Studies

Your search for Hematology | All Regions returned 27 studies.

 
Active, currently enrolling    Who can join   

An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

Keywords: Burkitt Lymphoma, Epstein-Barr Virus Infections, Herpesviridae Infections, DNA…
Study Type: INTERVENTIONAL   |  Region: California - Northern

Active, not yet recruiting    Who can join   

A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Keywords: Leukemia; Leukemia; Myeloid; Leukemia; Myeloid; Acute; Precursor Cell…
Study Type: INTERVENTIONAL   |  Region: California - Northern

Active, currently enrolling    Who can join   

Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy

Keywords: Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative…
Study Type: OBSERVATIONAL   |  Region: California - Northern

Enrollment complete    Who can join   

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Keywords: Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia;…
Study Type: INTERVENTIONAL   |  Region: California - Northern

Enrollment complete    Who can join   

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Keywords: Oncology (Adult);Hematology;
Study Type: INTERVENTIONAL   |  Region: California - Northern

Enrollment complete    Who can join   

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Keywords: Oncology (Adult);Hematology;
Study Type: INTERVENTIONAL   |  Region: California - Northern

Active, currently enrolling    Who can join   

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Keywords: Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia; Lymphoid;…
Study Type: INTERVENTIONAL   |  Region: California - Northern

123